Beam Therapeutics Inc. BEAM
25.15 USD -1.87 (-6.92%)
At closeNov 10, 2026, 6:33 PM EST
25.19 +0.04 +0.14%
After hours · Nov 10, 6:33 PM ET
23.60 Day range 27.00
20.60 52-week range 37.92
- YTD
- -9.27%
- 1 year
- +16.17%
News
globenewswire.com Beam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-cel in Patients with Sickle Cell Disease BEACON Trial Achieved Primary Efficacy Endpoint of Freedom from Severe Vaso-occlusive Crises (VOCs) for at Least 12 Consecutive Months, Based on Independently Adjudicated Results, and Met All Primary…
benzinga.com Guggenheim Maintains Buy on Beam Therapeutics, Lowers Price Target to $51 Guggenheim analyst Debjit Chattopadhyay maintains Beam Therapeutics (NASDAQ:BEAM) with a Buy and lowers the price target from $55 to $51.
benzinga.com Canaccord Genuity Maintains Buy on Beam Therapeutics, Lowers Price Target to $78 Canaccord Genuity analyst Whitney Ijem maintains Beam Therapeutics (NASDAQ:BEAM) with a Buy and lowers the price target from $79 to $78.
benzinga.com Wedbush Maintains Outperform on Beam Therapeutics, Raises Price Target to $30 Wedbush analyst David Nierengarten maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and raises the price target from $28 to $30.
benzinga.com Beam Therapeutics To Present Updated Data From Its BEACON Phase 1/2 Study Of Ristoglogene Autogetemcel In Sickle Cell Disease At 68th American Society of Hematology Annual Meeting Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated data from the BEACON…
globenewswire.com Beam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting BEACON Trial Results Selected for Official ASH Press Program Initial Patient-Reported Outcomes Demonstrate Early and Sustained Improvements in Physical Function, Pain, Fatigue, Emotional and Social…
zacks.com Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.17. This compares to a loss of $1.1 per share a year ago.
benzinga.com Beam Therapeutics Q3 EPS $(1.28) Misses $(1.15) Estimate, Sales $307.000K Miss $8.752M Estimate Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(1.28) per share which missed the analyst consensus estimate of $(1.15) by 11.3 percent. This is a 16.36 percent decrease over losses of…
globenewswire.com Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio Updated BEAM-302 Phase 1/2 Clinical Data Presented at ERS Demonstrated Durable Increases in Functional AAT and Reductions in Mutant Z-AAT; Completion of Dosing in the Global Pivotal Cohort Expected…
zacks.com 3 Promising Genomics Stocks to Add to Your Portfolio Now Genomics and synthetic biology are transforming healthcare through precision medicine and gene editing, putting ILMN, QURE and TXG in focus as the markets expand.
benzinga.com Bears Load Up on Ondas, Dutch Bros and 8 More Stocks — Is a Squeeze Brewing? Ondas, Dutch Bros and Under Armour are among the most-heavily shorted stocks in the market right now.
benzinga.com Canaccord Genuity Maintains Buy on Beam Therapeutics, Raises Price Target to $79 Canaccord Genuity analyst Whitney Ijem maintains Beam Therapeutics (NASDAQ:BEAM) with a Buy and raises the price target from $78 to $79.
zacks.com Beam Therapeutics (BEAM) Moves 15.6% Higher: Will This Strength Last? Beam Therapeutics (BEAM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price…- benzinga.com Wedbush Maintains Outperform on Beam Therapeutics, Lowers Price Target to $28 Wedbush analyst David Nierengarten maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and lowers the price target from $65 to $28.
seekingalpha.com Beam Therapeutics Inc. (BEAM) Reviews Initial Phase I II BEAM-301 Data in Glycogen Storage Disease Type 1a Transcript Beam Therapeutics Inc. (BEAM) Reviews Initial Phase I II BEAM-301 Data in Glycogen Storage Disease Type 1a Transcript
marketbeat.com Beam Therapeutics Reports Early BEAM-301 Gains in GSD1a Fasting Tolerance Beam Therapeutics NASDAQ: BEAM reported initial clinical data from its Phase I/II trial of BEAM-301, an investigational base-editing therapy for glycogen storage disease type 1A (GSD1a), showing…- benzinga.com Beam Therapeutics Announces Initial Data From Its Ongoing Phase 1/2 Clinical Trial Evaluating BEAM-301 For Treatment Of Glycogen Storage Disease Type Ia; In The 40 Mg Cohort, Two Patients Achieved 15 Hours Of Controlled Fasting; Safety Profile Of BEAM-301 Consistent With LNP-Based Therapies The data will be presented during a poster session at the 33rd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) in Hamburg, Germany. BEAM-301 is an investigational…
globenewswire.com Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual Congress In the 40 mg Cohort, Two Patients Achieved 15 Hours of Controlled Fasting, Improvements in Glucose Control and No Longer Required Starch Supplementation Following Treatment Safety Profile of BEAM-301…
defenseworld.net Insider Selling: Beam Therapeutics (NASDAQ:BEAM) CEO Sells $589,250.00 in Stock Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) CEO John Evans sold 25,000 shares of the business's stock in a transaction dated Thursday, October 15th. The stock was sold at an average price…
fool.com Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead? Cathie Wood owns Beam shares worth roughly $220 million, at the stock's current price. All of the company's revenue is collaboration revenue.
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. ("Beam" or the "Company") (NASDAQ: BEAM). Such investors are advised to…- benzinga.com HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $80 price target.
- benzinga.com Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target Wedbush analyst David Nierengarten reiterates Beam Therapeutics (NASDAQ:BEAM) with a Outperform and maintains $65 price target.
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. (“Beam” or the “Company”) (NASDAQ: BEAM). Such investors are advised…
benzinga.com Top 10 Powder Keg Stocks Where Short Sellers Are Sitting on a Fuse Short sellers are betting heavily against 10 stocks, and the fuse is getting shorter. Each one has more than 38% of its float sold short, with market caps above $2 billion and average daily volume…
benzinga.com Top 10 Powder Keg Stocks Where Short Sellers Are Sitting on a Fuse Dutch Bros, SoundHoundAI, Kohl's and Ondas are among the top ten most-heavily shorted stocks in the market right now.- benzinga.com Beam Therapeutics To Present Initial Data From Ongoing Phase 1/2 Clinical Trial Evaluating BEAM-301 For Treatment Of Glycogen Storage Disease Type Ia At 33rd Annual Congress Of ESGCT BEAM-301 Achieves Clinical Proof of Concept for Genetic Correction of R83C Mutation in GSDIaInitial Phase 1/2 Data Show Restoration of Endogenous Glucose Production Following a Single Treatment, with…
globenewswire.com Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress BEAM-301 Achieves Clinical Proof of Concept for Genetic Correction of R83C Mutation in GSDIa Initial Phase 1/2 Data Show Restoration of Endogenous Glucose Production Following a Single Treatment,…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. ("Beam" or the "Company") (NASDAQ: BEAM). Such investors are advised to…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. (“Beam” or the “Company”) (NASDAQ: BEAM). Such investors are advised…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. ("Beam" or the "Company") (NASDAQ: BEAM). Such investors are advised to…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. (“Beam” or the “Company”) (NASDAQ: BEAM). Such investors are…
seekingalpha.com Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress Beam Therapeutics is reaffirmed as a long-term buy, with significant upside expected around 2028–2029 as BEAM-302 advances. BEAM's pipeline leadership in AATD gene editing (BEAM-302) offers…
benzinga.com Squeeze Watch: 10 Stocks With Over 33% Short Interest Ten stocks have over 34% of their float short, with ONDS and BROS on the list led by VG.
benzinga.com Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets Cathie Wood’s ARKG bought Ionis, Beam, Veracyte and Scribe Therapeutics. Here are the biotech ETFs that also hold her latest bets.
benzinga.com These 10 Stocks Are Squeeze Candidates Waiting to Happen These 10 heavily shorted stocks face potential reversals, led by Venture Global, followed by CleanSpark and Dutch Bros.
benzinga.com Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target Wedbush analyst David Nierengarten reiterates Beam Therapeutics (NASDAQ:BEAM) with a Outperform and maintains $65 price target.
benzinga.com Beam Therapeutics Targets Accelerated FDA Approval for Base-Editing Treatment Beam Therapeutics reported positive Phase 1/2 trial data for BEAM-302 to treat AATD, targeting accelerated FDA approval with a 60 mg dose.- benzinga.com Beam Therapeutics Announces Updated Clinical Data From Its Phase 1/2 Trial Evaluating BEAM-302 For Alpha-1 Antitrypsin Deficiency; BEAM-302 Continues To Demonstrate Potential As One-Time Treatment For Both Lung And Liver Manifestations Of AATD With Up to 18 Months Follow-Up, Data Show Long-Term Durability of In Vivo Correction of Disease-causing Mutation with Single Dose of BEAM-302Treatment with BEAM-302 Increased Total and Functional AAT…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $80 price target.
benzinga.com Beam Therapeutics Q2 EPS $(1.18) Misses $(1.11) Estimate, Sales $490.000K Miss $16.370M Estimate Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(1.18) per share which missed the analyst consensus estimate of $(1.11) by 6.31 percent. This is a 18 percent decrease over losses of…
benzinga.com Beam Therapeutics To Present Updated Clinical Data From Phase 1/2 Trial Evaluating BEAM-302 For Alpha-1 Antitrypsin Deficiency At ERS Congress 2026 Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated clinical data from the…
benzinga.com Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case Prime Medicine won arbitration with Beam Therapeutics over PM647, avoiding damages and keeping its AATD gene-editing program on track.- benzinga.com B of A Securities Reiterates Buy on Beam Therapeutics, Maintains $47 Price Target B of A Securities analyst Alec Stranahan reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $47 price target.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $80 price target.
benzinga.com Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze (CORRECTED) Data show high levels of short interest in 10 stocks, including Avis Budget, RH, Lucid and CleanSpark.- benzinga.com The FDA Clears Beam Therapeutics' Investigational New Drug Application For BEAM-304 For Phenylketonuria Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration…
- benzinga.com Beam Therapeutics Presented Clinical Data From Phase 1/2 Trial For BEAM-302 Treatment For Alpha-1 Antitrypsin Deficiency At American Thoracic Society International Conference In Orlando, FL BEAM-302 is being evaluated in a Phase 1/2, open-label, dose exploration and dose expansion clinical trial to investigate its safety, tolerability, pharmacodynamics, pharmacokinetics and efficacy.…
- benzinga.com Bernstein Maintains Outperform on Beam Therapeutics, Lowers Price Target to $39 Bernstein analyst William Pickering maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and lowers the price target from $40 to $39.
benzinga.com Jim Cramer: This Tech Stock Is A 'Winner', Snap Does Not Have Growth Jim Cramer discussed various stocks on Mad Money Lightning Round. He expressed concerns about Ondas Inc's losses and praised companies like Halliburton and Nokia.